Neurocrine Biosciences, Inc. (LON: 0K6R)

Market Cap	12.06B
Revenue (ttm)	1.67B
Net Income (ttm)	287.92M
Shares Out	n/a
EPS (ttm)	2.78
PE Ratio	41.90
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,552
Average Volume	952
Open	146.66
Previous Close	144.62
Day's Range	145.39 - 146.99
52-Week Range	89.66 - 146.99
Beta	n/a
RSI	70.88
Earnings Date	Feb 7, 2025

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to trea...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1992
• Employees: 1,400
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K6R

Financial Performance

In 2023, Neurocrine Biosciences's revenue was $1.89 billion, an increase of 26.76% compared to the previous year's $1.49 billion. Earnings were $249.70 million, an increase of 61.62%.

Financial numbers in USD